Parallel drug developments in DPP-4 inhibitors to enhance the actions of endogenous GLP-1 led to the release of the gliptans, the first of which was sitagliptin, which was Food and Drug Administration (FDA) approved in 2006
This dual receptor activation distinguishes tirzepatide from single-agonist GLP-1 receptor agonists
Diabetes meds are available only with a doctors prescription
This sterilizes the point of entry for the needle
You do not just want to be smaller and softer
Use of Liraglutide (Victoza, Saxenda) & Semaglutide (Ozempic, Wegovy, Rybelsus) Comes with Risk of Gastrointestinal Disorders Use of Liraglutide (Victoza, Saxenda) & Semaglutide (Ozempic, Wegovy, Rybelsus) Tied to Increased Risk for Pancreatitis and Bowel Obstruction A new study showed that use of the GLP1 agonist medications approved for diabetes and weight loss including liraglutide (Victoza, Saxenda) & semaglutide (Ozempic, Wegovy, Rybelsus) come with a 9X increased risk of pancreatitis, 4X increased risk of bowel obstruction and 3.5X increased risk of gastroparesis compared to controls
